Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

Blood (2024) 144 (17): 1813–1820.

https://doi.org/10.1182/blood.2024025802

Published: 2024

Journal Articles

Perioperative Outcomes and Management in Patients with Myeloproliferative Neoplasms: A Multicentric Retrospective Analysis of 354 Surgical Interventions

Natasha Szuber, Steve Dagenais-Bellefeuille, Mégane Tanguay, Awatef Shehabeldeen, Saima Ahmed, Michaël Harnois, Jaroslav F. Prchal, Harold J. Olney, Lambert Busque, Shireen Sirhan

Blood (2023) 142 (Supplement 1): 3183.

https://doi.org/10.1182/blood-2023-188259

Published: 2023

Journal Articles

Clinical Effectiveness and Safety of Momelotinib Compared with Continued Ruxolitinib or Best Available Therapy in Patients with Myelofibrosis Who Required RBC Transfusions: Subgroup Analysis of the Phase 3 Simplify-2 Study

Claire N Harrison, Alessandro Maria Vannucchi, Christian Recher, Francesco Passamonti, Aaron T. Gerds, Juan Carlos Hernandez Boluda, Abdulraheem Yacoub, Shireen Sirhan, Jun Kawashima, Bharat Patel, Bryan Strouse, Uwe Platzbecker

Blood (2023) 142 (Supplement 1): 3189.

https://doi.org/10.1182/blood-2023-178816

Published: 2023

Journal Articles

Prospective Symptom Burden Analysis in 784 Patients with Myeloproliferative Neoplasms: High Burden Correlates with Inflammatory/Genetic Biomarkers and Reduced Survival

Alisa Poullet, Lambert Busque, Shireen Sirhan, Robert Delage, Ghislain Cournoyer, Ines Chamakhi, Danielle Talbot, Luigina Mollica, Daniele Marceau, Vincent Ethier, Pierre Desjardins, Harold J. Olney, Michaël Harnois, Natasha Szuber

Blood (2023) 142 (Supplement 1): 917.

https://doi.org/10.1182/blood-2023-183005

Published: 2023

Journal Articles

Higher Rates of Perioperative Thrombosis and Distinct Management Practices in Secondary Erythrocytosis Versus Polycythemia Vera

Natasha Szuber, Michael Harnois, Robert Delage, Shireen Sirhan, Lambert Busque

Blood (2022) 140 (Supplement 1): 5661–5663.

https://doi.org/10.1182/blood-2022-170026

Published: 2022

Journal Articles

Very Elderly Patients with Myeloproliferative Neoplasms: Phenotypic Distinctions and Prognostic Determinants of Complications and Mortality

Judith Jolin, Michael Harnois, Luigina Mollica, Pierre Laneuville, Robert Delage, Harold J. Olney, Shireen Sirhan, Lambert Busque, Natasha Szuber

Blood (2021) 138 (Supplement 1): 2572.

https://doi.org/10.1182/blood-2021-145131

Published: 2021

Journal Articles

Role of Allogeneic Hematopoietic Cell Transplant in Patients with Myelofibrosis in the JAK Inhibitor Era

Blood (2020) 136 (Supplement 1): 52–53.

https://doi.org/10.1182/blood-2020-141790

Published: 2020

Journal Articles

Secondary Erythrocytosis Is Phenotypically Distinct from Polycythemia Vera but Associated with Comparable Rates of Thrombosis at Diagnosis

Eliane Nguyen, MD, Natasha Szuber, MD, Michael Harnois, Lambert Busque, MD, Luigina Mollica, MD FRCPC, PhD, Sarit E Assouline, MD MSc, Ines Chamakhi, MD MD FRCP(C), Harold J. Olney, MD, Shireen Sirhan, MD

Blood (2020) 136 (Supplement 1): 4–7.

https://doi.org/10.1182/blood-2020-141835

Published: 2020

Journal Articles

MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis

John Mascarenhas, MD, Marina Kremyanskaya, Ronald Hoffman, MD, Prithviraj Bose, MD, Moshe Talpaz, MD, Claire N Harrison, Professor, Vikas Gupta, MD FRCP, FRCPath, Brian Leber, MD, Shireen Sirhan, MD, Sujan Kabir, MD, Adrian Senderowicz, MD, James Shao, MS, Jennifer Mertz, PhD, Patrick Trojer, PhD, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 670.

https://doi.org/10.1182/blood-2019-127119

Published: 2019

Journal Articles

3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups

Natasha Szuber, MD, Mythri Mudireddy, MBBS, Maura Nicolosi, MD, Domenico Penna, MD, Rangit Vallapureddy, MBBS, Terra L. Lasho, PhD, Christy Finke, BS, Kebede H. Begna, MD, Michelle A. Elliott, MD, C. Christopher Hook, MD, Alexandra Wolanskyj, MD, Mrinal M. Patnaik, MD MBBS, Curtis A. Hanson, MD, Rhett P. Ketterling, Shireen Sirhan, MD, Animesh Pardanani, MBBS, PhD, Naseema Gangat, MBBS, Lambert Busque, MD, Ayalew Tefferi, MD

Blood (2018) 132 (Supplement 1): 3035.

https://doi.org/10.1182/blood-2018-99-109740

Published: 2018

Journal Articles

Circulating Cytokines and Markers of Iron Metabolism in Myelofibrosis Patients Treated with Momelotininb: Correlatives from the Ym-387-II Study

Vikas Gupta, MD FRCP, FRCPath, Ruben A. Mesa, Michael W Deininger, MD PhD, Candido E. Rivera, MD, Shireen Sirhan, MD FRCP, Srdan Verstovsek, MD, Yafeng Zhang, PhD, Yuanyuan Xiao, PhD, Helen Collins, MD, Kevin Kwei, Adarsh Joshi, PhD, Carrie Baker Brachmann, PhD

Blood (2015) 126 (23): 1600.

https://doi.org/10.1182/blood.V126.23.1600.1600

Published: 2015

Journal Articles

Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis

Animesh Pardanani, MBBS, PhD, Jason Gotlib, MD, MS, Vikas Gupta, MD, FRCP, FRCPath, Andrew W. Roberts, MBBS, PhD, Martha Wadleigh, MD, Shireen Sirhan, MD, FRCP, Linda M Bavisotto, MD, Jun Kawashima, MD, Peter Lee, MD, PhD, Mark Kowalski, MD, PhD, Wei Deng, PhD, Demi Niforos, MS, Ayalew Tefferi, MD

Blood (2013) 122 (21): 108.

https://doi.org/10.1182/blood.V122.21.108.108

Published: 2013

Journal Articles

Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis

Animesh Pardanani, MBBS, PhD, Jason Gotlib, Vikas Gupta, MD, FRCP, FRCPath, Andrew W. Roberts, MBBS, PhD, Martha Wadleigh, MD, Shireen Sirhan, MD, FRCP, Linda M Bavisotto, MD, Jun Kawashima, MD, Mark Kowalski, MD, PhD, Ayalew Tefferi, MD

Blood (2012) 120 (21): 178.

https://doi.org/10.1182/blood.V120.21.178.178

Published: 2012

Journal Articles

An Expanded Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis,

Animesh Pardanani, MBBS, PhD, Jason Gotlib, M.D., M.S., Vikas Gupta, MD, FRCP, FRCPath, Andrew W Roberts, MBBS, PhD, Martha Wadleigh, MD, Shireen Sirhan, MD, FRCP, Mark R. Litzow, MD, William J Hogan, MBBCh, Kebede Begna, MD, Gregg Smith, PhD, MBA, Linda M Bavisotto, MD, Mark Kowalski, MD, PhD, Ayalew Tefferi, MD

Blood (2011) 118 (21): 3849.

https://doi.org/10.1182/blood.V118.21.3849.3849

Published: 2011

Journal Articles

Oligonucleotide Array CGH Studies in Myeloproliferative Neoplasms and Comparison with Conventional Cytogenetic Analysis

Ayalew Tefferi, MD, Shireen Sirhan, MD, Yi Sun, PhD, Terra L. Lasho, MT(ASCP), Charles A. LeDuc, PhD, Christy M. Finke, James Weisberger, MD, Sherri Bale, PhD, John Compton, PhD, Animesh Pardanani, MD, PhD, Erik C. Thorland, PhD, Yuriy Shevchenko, PhD, Marc D. Grodman, MD, Wendy K. Chung, MD, PhD

Blood (2007) 110 (11): 1550.

https://doi.org/10.1182/blood.V110.11.1550.1550

Published: 2007

Journal Articles

The Presence of the JAK2 V617F Mutation in Primary Myelofibrosis and Its Allele Burden in Polycythemia Vera Predict Chemosensitivity to Hydroxyurea.

Shireen Sirhan, MD, Jocelin Huang, MD, Chin-Yang Li, MD, Ayalew Tefferi, MD

Blood (2007) 110 (11): 3539.

https://doi.org/10.1182/blood.V110.11.3539.3539

Published: 2007

Journal Articles

The Clinical and PRV-1 Expression Phenotype of Wild-Type, Heterozygous, and Homozygous JAK2 V617F in Polycythemia Vera.

Ayalew Tefferi, MD, Shireen Sirhan, MD, Terra L. Lasho, MT, ASCP, Susan M. Schwager, Jacob S. Strand, Michelle A. Elliott, MD, Ruben A. Mesa, MD, Alexandra P. Wolanskyj, MD, David P. Steensma, MD, Chin Yang Li, MD, Martha Wadleigh, MD, Stephanie J. Lee, MD, D. Gary Gilliland, MD, PhD

Blood (2005) 106 (11): 255.

https://doi.org/10.1182/blood.V106.11.255.255

Published: 2005

Journal Articles

Blood CD34 Count in Myelofibrosis with Myeloid Metaplasia: A Prospective Evaluation of Prognostic Value in 94 Patients.

Brijesh Arora, MD, Shireen Sirhan, MD, James D. Hoyer, MD, Ruben A. Mesa, MD, Ayalew Tefferi, MD

Blood (2004) 104 (11): 662.

https://doi.org/10.1182/blood.V104.11.662.662

Published: 2004

Journal Articles

Neutrophil and Eosinophil PRV-1 Expression in Atypical Myeloproliferative Disorders.

Shireen Sirhan, Terra L. Lasho, Michelle A. Elliott, Ayalew Tefferi

Blood (2004) 104 (11): 1521.

https://doi.org/10.1182/blood.V104.11.1521.1521

Published: 2004

Journal Articles

Red Cell Mass Measurement in Polycythemia: Evaluation of Performance and Added Value.

Shireen Sirhan, MD, Ayalew Tefferi, MD

Blood (2004) 104 (11): 1525.

https://doi.org/10.1182/blood.V104.11.1525.1525

Published: 2004

NARROW

Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

Perioperative Outcomes and Management in Patients with Myeloproliferative Neoplasms: A Multicentric Retrospective Analysis of 354 Surgical Interventions

Clinical Effectiveness and Safety of Momelotinib Compared with Continued Ruxolitinib or Best Available Therapy in Patients with Myelofibrosis Who Required RBC Transfusions: Subgroup Analysis of the Phase 3 Simplify-2 Study

Prospective Symptom Burden Analysis in 784 Patients with Myeloproliferative Neoplasms: High Burden Correlates with Inflammatory/Genetic Biomarkers and Reduced Survival

Higher Rates of Perioperative Thrombosis and Distinct Management Practices in Secondary Erythrocytosis Versus Polycythemia Vera

Very Elderly Patients with Myeloproliferative Neoplasms: Phenotypic Distinctions and Prognostic Determinants of Complications and Mortality

Role of Allogeneic Hematopoietic Cell Transplant in Patients with Myelofibrosis in the JAK Inhibitor Era

Secondary Erythrocytosis Is Phenotypically Distinct from Polycythemia Vera but Associated with Comparable Rates of Thrombosis at Diagnosis

MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis

3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups

Circulating Cytokines and Markers of Iron Metabolism in Myelofibrosis Patients Treated with Momelotininb: Correlatives from the Ym-387-II Study

Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis

Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis

An Expanded Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis,

Oligonucleotide Array CGH Studies in Myeloproliferative Neoplasms and Comparison with Conventional Cytogenetic Analysis

The Presence of the JAK2 V617F Mutation in Primary Myelofibrosis and Its Allele Burden in Polycythemia Vera Predict Chemosensitivity to Hydroxyurea.

The Clinical and PRV-1 Expression Phenotype of Wild-Type, Heterozygous, and Homozygous JAK2 V617F in Polycythemia Vera.

Blood CD34 Count in Myelofibrosis with Myeloid Metaplasia: A Prospective Evaluation of Prognostic Value in 94 Patients.

Neutrophil and Eosinophil PRV-1 Expression in Atypical Myeloproliferative Disorders.

Red Cell Mass Measurement in Polycythemia: Evaluation of Performance and Added Value.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only